Company Description
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide.
The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care.
The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.
It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies.
The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision.
The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries.
It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure.
Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
| Country | United States |
| Founded | 1931 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 60,000 |
| CEO | Jose E. Almeida |
Contact Details
Address: One Baxter Pkwy, Df2-1w Deerfield, Illinois 60015 United States | |
| Phone | (847) 948-2000 |
| Website | baxter.com |
Stock Details
| Ticker Symbol | BAX |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000010456 |
| CUSIP Number | 071813109 |
| ISIN Number | US0718131099 |
| Employer ID | 36-0781620 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Jose E. Almeida | Chairman of the Board, President and Chief Executive Officer |
| Joel T. Grade | Executive Vice President and Chief Financial Officer |
| Heather Knight | Executive Vice President and Group President of Medical Products and Therapies |
| Alok Sonig B.E., Mba | Executive Vice President and Group President of Pharmaceuticals |
| Christopher A. Toth | Executive Vice President and Group President of Kidney Care |
| Talvis P. Love | Senior Vice President and Chief Information Officer |
| Tobi Karchmer M.D., M.S. | Senior Vice President and Chief Medical and Scientific Officer |
| Clare Trachtman | Vice President of Investor Relations |
| David S. Rosenbloom | Executive Vice President and General Counsel |
| Stacey Eisen | ?Senior Vice President, Chief Communications Officer and Corporate Marketing? |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 25, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 14, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 4, 2024 | 8-K | Current Report |
| Mar 1, 2024 | 144 | Filing |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 8, 2024 | 10-K | Annual Report |